The Food and Drug Administration is once again making public the letters it sends to drug companies when it declines to approve their products.
According to Endpoints News, the FDA on Friday posted 14 new rejection letters online. These documents are known as complete response letters, or CRLs — the notices the agency issues to a pharmaceutical company when it will not approve a drug in its current form.
The move marks a return to disclosure after a brief interruption. Endpoints News reports that the postings came just days after the Department of Health and Human Services (HHS) confirmed to the outlet that the FDA had paused new CRL releases. HHS attributed that pause to a pharma-backed concern, according to Endpoints News.
The back-and-forth matters because rejection letters have historically been kept private, leaving investors, patients, and the public in the dark about exactly why a given medicine failed to win approval. When the FDA publishes them, outsiders can see the agency's specific reasoning — the safety questions, manufacturing issues, or gaps in clinical data that stood in the way. That transparency can shape how companies talk about setbacks and how closely their public statements match the regulator's actual findings.
By resuming the releases with a batch of 14 letters, the FDA is signaling — at least for now — that these documents will keep flowing into public view, even after a pause that Endpoints News says was tied to industry pushback.
Why it matters: whether the FDA routinely publishes its rejection letters determines how much the public can independently verify why drugs get turned down, rather than relying on companies' own accounts.